PDF(Pubmed)
Abstract：
BACKGROUND: Ghost cell odontogenic carcinoma is a rare malignant odontogenic carcinoma characterized by the presence of ghost cells. It has a nonspecific clinical and radiographic presentation and can be locally destructive and invasive, sometimes with distant metastases. However, no effective systemic therapy is currently recommended for such patients.
METHODS: The patient has been unable to undergo surgery or radiotherapy again. Therefore, he was referred to our department for a more aggressive, multimodal systematic treatment program.
METHODS: The histopathological examination was morphologically suggestive of ghost cell odontogenic carcinomas.
METHODS: We report a case of locally invasive primary inoperable odontogenic shadow cell carcinoma in a 31-year-old Chinese man who achieved treatment with Toripalimab and chemotherapy, followed by Toripalimab maintenance therapy after 6 cycles.
RESULTS: He achieved partial remission after treatment. The quality of life significantly improved after treatment. There were no grade 3/4 treatment-related adverse events during treatment.
CONCLUSIONS: This case presented that Toripalimab and chemotherapy may be a safe and effective systemic therapy for ghost cell odontogenic carcinoma.
METHODS: The patient has been unable to undergo surgery or radiotherapy again. Therefore, he was referred to our department for a more aggressive, multimodal systematic treatment program.
METHODS: The histopathological examination was morphologically suggestive of ghost cell odontogenic carcinomas.
METHODS: We report a case of locally invasive primary inoperable odontogenic shadow cell carcinoma in a 31-year-old Chinese man who achieved treatment with Toripalimab and chemotherapy, followed by Toripalimab maintenance therapy after 6 cycles.
RESULTS: He achieved partial remission after treatment. The quality of life significantly improved after treatment. There were no grade 3/4 treatment-related adverse events during treatment.
CONCLUSIONS: This case presented that Toripalimab and chemotherapy may be a safe and effective systemic therapy for ghost cell odontogenic carcinoma.
摘要：
背景：鬼细胞牙源性癌是一种罕见的恶性牙源性癌，其特征是存在鬼细胞。它具有非特异性的临床和影像学表现，可以是局部破坏性和侵入性的，有时有远处转移。然而,目前未推荐对此类患者进行有效的全身治疗.
方法：患者无法再次接受手术或放疗。因此,他被转介给我们部门，多模式系统治疗方案。
方法：组织病理学检查在形态学上提示鬼细胞牙源性癌。
方法：我们报告一例31岁的中国男性局部浸润性原发性无法手术的牙源性影细胞癌，该患者接受了托里帕利马和化疗，6个周期后给予托里帕利马维持治疗。
结果：治疗后部分缓解。治疗后生活质量明显改善。治疗期间无3/4级治疗相关不良事件发生。
结论：本病例提示托里帕利单抗联合化疗可能是治疗牙源性鬼细胞癌安全有效的全身治疗方法。
方法：患者无法再次接受手术或放疗。因此,他被转介给我们部门，多模式系统治疗方案。
方法：组织病理学检查在形态学上提示鬼细胞牙源性癌。
方法：我们报告一例31岁的中国男性局部浸润性原发性无法手术的牙源性影细胞癌，该患者接受了托里帕利马和化疗，6个周期后给予托里帕利马维持治疗。
结果：治疗后部分缓解。治疗后生活质量明显改善。治疗期间无3/4级治疗相关不良事件发生。
结论：本病例提示托里帕利单抗联合化疗可能是治疗牙源性鬼细胞癌安全有效的全身治疗方法。
